About
The Viral Hepatitis National Progress Report provides information on progress toward 2025 goals for new viral hepatitis infections and viral hepatitis–related deaths, overall and for key populations.
![2024 National Progress Report 2024 Hepatitis National Progress Report](/hepatitis/media/images/2024/12/cdc-hepatitis-2024-national-progress-report.png)
Progress
Ten objective indicators assess progress toward achieving key viral hepatitis goals. Select the indicator from the table below for more information.
![a green square with a checkmark in the center](/hepatitis/media/images/2024/12/cdc-dvh-npr-asr-status-met.png)
Met or exceeded current annual target
![a yellow square with a right pointing arrow in the center](/hepatitis/media/images/2024/12/cdc-dvh-npr-asr-status-same.png)
Moving toward annual target, but annual target was not fully met
![a red square with an X in the center](/hepatitis/media/images/2024/12/cdc-dvh-npr-asr-status-didnotmeet.png)
Annual target was not met and has not changed or moved away from annual target
Baseline 2017 data year |
2022 Observed (Annual target*) |
2025 Goal 2023 data year |
Trend | 2022 Status | |
---|---|---|---|---|---|
Hepatitis A | |||||
Reduce estimated† new hepatitis A virus infections by ≥40% | 6,700 | 4,500 (4,450) |
4,000 | ![]() |
![]() |
Hepatitis B | |||||
Reduce estimated† new hepatitis B virus infections by ≥20% | 22,200 | 13,800 (18,700) |
18,000 | ![]() |
![]() |
Reduce reported rate‡ of new hepatitis B virus infections among persons who inject drugs¶ by ≥25% | 1.4 | 0.6 (1.1) |
1.0 | ![]() |
![]() |
Reduce reported rate‡ of hepatitis B-related deaths by ≥20% | 0.46 | 0.44 (0.39) |
0.37 | ![]() |
![]() |
Reduce reported rate‡ of hepatitis B-related deaths among non-Hispanic Asian/Pacific Islander persons by ≥25% | 2.45 | 2.30 (1.94) |
1.84 | ![]() |
![]() |
Hepatitis C | |||||
Reduce estimated† new hepatitis C virus infections by ≥20% | 44,700 | 67,400 (36,617) |
35,000 | ![]() |
![]() |
Reduce reported rate‡ of new hepatitis C virus infections among persons who inject drugs¶ by ≥25% | 2.3 | 2.7 (1.8) |
1.7 | ![]() |
![]() |
Reduce reported rate‡ of hepatitis C-related deaths by ≥20% | 4.13 | 2.89 (3.19) |
3.00 | ![]() |
![]() |
Reduce reported rate‡ of hepatitis C-related deaths among non-Hispanic American Indian/Alaska Native persons by ≥30% | 10.24 | 9.08 (7.68) |
7.17 | ![]() |
![]() |
Reduce reported rate‡ of hepatitis C-related deaths among non-Hispanic Black persons by ≥30% | 7.03 | 4.75 (5.27) |
4.92 | ![]() |
![]() |
* Annual targets assume a constant (linear) rate of change from the observed baseline (2017) to the 2025 goal (2023 data year). † The number of estimated viral hepatitis infections was determined by multiplying the number of reported cases by a factor that adjusted for underascertainment and underreporting (CDC 2022 Viral Hepatitis Surveillance Report and Klevens et al., 2014). ‡ Per 100,000 population. ¶ Persons aged 18–40 years were used as a proxy for persons who inject drugs. |